# Recombinant Human Interleukin-17A/IL-17A Protein

Catalog Number: PKSH032620



Note: Centrifuge before opening to ensure complete recovery of vial contents.

| -   |    |     |     |        |   |
|-----|----|-----|-----|--------|---|
| - 1 | 00 | cri | m   | 17     | ٦m                                      |
| J   |    |     | 174 | , T. U | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |

 Species
 Human

 Mol\_Mass
 16.5 kDa

 Accession
 Q16552

**Bio-activity** Measure by its ability to induce IL-6 secretion in 3T3 cells. The  $ED_{50}$  for this effect is

<6 ng/mL.

## **Properties**

**Purity** > 98 % as determined by reducing SDS-PAGE.

**Endotoxin** < 0.01 EU per µg of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

**Shipping** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation** Lyophilized from sterile PBS,pH 8.0.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

**Reconstitution** Please refer to the printed manual for detailed information.

#### Data



> 98 % as determined by reducing SDS-PAGE.

### Background

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha; it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis; and produced by rheumatoid arthritis synovium. It increases IL-6 production; induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

#### For Research Use Only